Stephen G. Machatha
2023
In 2023, Stephen G. Machatha earned a total compensation of $1.6M as Chief Development Officer at Aldeyra Therapeutics, a 38% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $113,175 |
|---|---|
| Option Awards | $1,089,483 |
| Salary | $377,250 |
| Other | $13,200 |
| Total | $1,593,108 |
Machatha received $1.1M in option awards, accounting for 68% of the total pay in 2023.
Machatha also received $113.2K in non-equity incentive plan, $377.3K in salary and $13.2K in other compensation.
Rankings
In 2023, Stephen G. Machatha's compensation ranked 745th out of 3,006 executives tracked by ExecPay. In other words, Machatha earned more than 75.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 745 out of 3,006 | 75th |
Division Manufacturing | 426 out of 1,650 | 74th |
Major group Chemicals And Allied Products | 289 out of 918 | 69th |
Industry group Drugs | 283 out of 881 | 68th |
Industry Pharmaceutical Preparations | 187 out of 637 | 71st |
Source: SEC filing on April 22, 2024.
Machatha's colleagues
We found two more compensation records of executives who worked with Stephen G. Machatha at Aldeyra Therapeutics in 2023.